HC Wainwright Has Optimistic Outlook of BioNTech Q2 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Stock analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of BioNTech in a research note issued on Wednesday, June 25th. HC Wainwright analyst R. Burns now expects that the company will earn $3.78 per share for the quarter, up from their prior estimate of $3.72. HC Wainwright has a “Buy” rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

BNTX has been the topic of several other reports. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. Citigroup reiterated a “buy” rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a report on Thursday, May 22nd. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Finally, BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $137.86.

BioNTech Price Performance

NASDAQ:BNTX opened at $104.80 on Thursday. The firm has a market cap of $25.19 billion, a price-to-earnings ratio of -30.82 and a beta of 1.29. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $102.49 and its two-hundred day moving average is $107.40.

Institutional Trading of BioNTech

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in BioNTech by 39.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company’s stock valued at $21,349,000 after acquiring an additional 53,319 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in BioNTech in the fourth quarter valued at approximately $584,000. GAMMA Investing LLC grew its position in BioNTech by 5,710.8% in the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company’s stock valued at $4,884,000 after acquiring an additional 52,711 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in BioNTech in the fourth quarter valued at approximately $238,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.